


Ask a doctor about a prescription for REFACTO AF 2000 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION IN PRE-FILLED SYRINGE
Package Leaflet: Information for the User
ReFacto AF 250UI powder and solvent for solution for injection in pre-filled syringe
ReFacto AF 500UI powder and solvent for solution for injection in pre-filled syringe
ReFacto AF 1000UI powder and solvent for solution for injection in pre-filled syringe
ReFacto AF 2000UI powder and solvent for solution for injection in pre-filled syringe
ReFacto AF 3000 UI powder and solvent for solution for injection in pre-filled syringe
moroctocog alfa (recombinant human coagulation factor VIII)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack:
ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII. Factor VIII is necessary for blood to clot and stop bleeding. In patients with haemophilia A (congenital factor VIII deficiency), it is either not present or does not work properly.
ReFacto AF is used to treat and prevent (prophylaxis) bleeding episodes in adults and children of all ages (including newborns) with haemophilia A.
Do not use ReFacto AF
Talk to your doctor if you are unsure.
Warnings and precautions
Talk to your doctor or pharmacist before starting ReFacto AF
Other medicines and ReFacto AF
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy, breast-feeding, and fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
ReFacto AF has no influence on the ability to drive and use machines.
ReFacto AF contains sodium
After reconstitution, ReFacto AF contains 1.27 mmol (or 29 mg) of sodium (a major component of cooking/table salt) per pre-filled syringe. This is equivalent to 1.5% of the maximum recommended daily intake of sodium for an adult. Depending on your body weight and your dose of ReFacto AF, you may receive multiple pre-filled syringes. This should be taken into consideration if you are on a low-salt diet.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again.
Treatment with ReFacto AF should be started by a doctor experienced in the treatment of patients with haemophilia A. Your doctor will decide the dose of ReFacto AF you should receive. This dose and its duration will depend on your individual needs for factor VIII replacement therapy. ReFacto AF is given by injection into a vein and the injection takes several minutes. Injections of ReFacto AF can be given by the patients or by their caregivers, provided they have received appropriate training.
During your treatment, your doctor may change the dose of ReFacto AF you receive.
Consult your doctor before travelling. When you travel, you should carry your factor VIII product in sufficient quantity for the planned treatment.
It is recommended that each time you administer ReFacto AF, you record the name on the label and the batch number of the product. You can stick one of the detachable labels found on the pre-filled syringe to document the batch number in your diary or to report any side effects.
Reconstitution and administration
The following instructions are a guide for the reconstitution and administration of ReFacto AF supplied in a pre-filled syringe. Patients should follow the specific reconstitution and administration instructions given by their doctors.
ReFacto AF is administered by intravenous (IV) infusion after reconstitution. The pre-filled syringe is made up of two chambers, one chamber contains the lyophilized ReFacto AF powder and the other chamber contains the solvent [sodium chloride 9 mg/ml (0.9%) solution]. Throughout these instructions, this device will be referred to as the pre-filled syringe.
For reconstitution, use only the pre-filled syringe provided in the pack. For administration, other sterile disposable syringes may be used.
ReFacto AF must not be mixed with other infusion solutions.
Note: If you need to use more than one pre-filled syringe of ReFacto AF per infusion, each pre-filled syringe must be reconstituted according to the specific instructions. To withdraw the reconstituted contents from each pre-filled syringe, a 10 ml syringe or a larger syringe with a luer lock (not included in this kit) may be used (refer to Additional Instructions).
Preparation
Reconstitution

During the reconstitution process, it is important to keep the ReFacto AF pre-filled syringe in a vertical position (with the white powder on top of the clear solution) to prevent possible leaks.

While holding the ReFacto AF pre-filled syringe in a vertical position, remove the grey rubber stopper and replace it with the blue vent cap. This vent cap has small holes that allow air to escape to prevent a pressure increase. Avoid touching the open end of the pre-filled syringe or the blue vent cap.

Note: To prevent fluid leakage from the tip of the pre-filled syringe, do not push the plunger with excessive force.


Inspect the final solution visually for particulate matter or discoloration. The solution should have a transparent to slightly opalescent appearance and be colourless. Discard the pre-filled syringe if particles or discoloration are observed.

ReFacto AF must be used within 3 hours after reconstitution or after the grey stopper has been removed from the pre-filled syringe.
If you are not going to use the ReFacto AF solution immediately, you should store the pre-filled syringe in a vertical position, with the blue vent cap on the pre-filled syringe until you are ready for infusion. The reconstituted solution can be stored at room temperature for up to 3 hours. If you have not used it within 3 hours, discard it.
Administration (Intravenous Infusion)
Your doctor or another healthcare professional will teach you how to perform the infusion of ReFacto AF. Once you have learned how to perform self-infusion, you can follow the instructions included in this leaflet.
ReFacto AF is administered by intravenous (IV) infusion after reconstitution of the powder with the solvent (0.9% sodium chloride). Once reconstituted and before administration, ReFacto AF must be inspected visually for particulate matter or discoloration.
ReFacto AF should be administered using the infusion system included in this kit, unless your doctor or another healthcare professional has given you different instructions.



Reconstituted ReFacto AF must not be administered in the same tube or container with other medicines.
Note: Discard the unused solution, the empty pre-filled syringe, and the used medical materials in an appropriate container for disposing of medical waste, as these materials may harm others if not disposed of properly.

It is recommended to record the batch number found on the label of the ReFacto AF pre-filled syringe each time you use ReFacto AF. You can use the detachable label from the ReFacto AF pre-filled syringe to record the batch number.
Additional Instructions:
Reconstituting multiple ReFacto AF pre-filled syringes to a 10 ml syringe or a larger syringe with a luer lock (10 ml syringes or luer lock syringes are not provided in the kit).
The following instructions are for the use of multiple ReFacto AF pre-filled syringe kits with a 10 ml syringe or a larger syringe with a luer lock.
Hold the ReFacto AF pre-filled syringe in a vertical position, slowly push the plunger until almost, but not all, the air has been eliminated from the chamber where the product is located.



Note: Discard the unused solution, the empty pre-filled syringe, and the used medical materials in an appropriate container for disposing of medical waste, as these materials may harm others if not disposed of properly.

If you use more ReFacto AF than you should
Talk to your doctor or pharmacist.
If you stop using ReFacto AF
Do not stop using ReFacto AF without consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine may cause adverse effects, although not all people suffer from them.
Allergic Reactions
If allergic reactions(anaphylactic) sudden, severeappear, the infusion must be stopped immediately. You should consult your doctor immediatelyif you present any of the following early symptoms of allergic reactions:
Severe symptoms, such as difficulty breathing and fainting (or near-fainting), require rapid emergency treatment. Sudden, severe allergic reactions (anaphylactic) are rare (may affect up to 1 in 100 patients)
Development of Inhibitors
In children who have not received previous treatment with medicines composed of factor VIII, inhibitory antibodies (see section 2) may occur very frequently (more than 1 in 10 patients); however, in patients who have received previous treatment with factor VIII (more than 150 days of treatment), the risk is rare (less than 1 in 100 patients). If this happens, the medicines you or your child take may stop working properly and you or your child may suffer from persistent bleeding. In that case, contact your doctor immediately.
Very Common Adverse Effects(may affect more than 1 in 10 patients)
Common Adverse Effects(may affect up to 1 in 10 patients)
Uncommon Adverse Effects(may affect up to 1 in 100 patients)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the outer packaging and on the label of the pre-filled syringe after CAD. The expiration date is the last day of the month indicated.
Store and transport refrigerated (between 2°C and 8°C). Do not freeze to avoid damaging the pre-filled syringe.
For your convenience, the medicine can be removed from storage and stored at room temperature (up to 25°C) for a single period of 3 months maximum. At the end of this room temperature storage period, the product must not be refrigerated again, but must be used or discarded. Note on the outer packaging the date on which ReFacto AF in pre-filled syringe is removed from the refrigerator and placed at room temperature (up to 25°C). Keep the pre-filled syringe inside the outer packaging to protect it from light.
The reconstituted product must be used within 3 hours of reconstitution or removal of the gray cap.
The solution will be clear to slightly opalescent and colorless. Do not use this medicine if you notice that it is turbid or contains visible particles.
Medicines should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.
Composition of ReFacto AF
For the reconstitution of moroctocog alfa, a solvent [sodium chloride injection solution 9 mg/ml (0.9%)] is included in the ReFacto AF pre-filled syringe.
Appearance of the Product and Package Contents
ReFacto AF is a pre-filled syringe with powder and solvent for injection solution that contains ReFacto AF powder in the upper chamber and the solvent [sodium chloride injection solution 9 mg/ml (0.9%)] in the lower chamber.
The package contents are:
Marketing Authorization Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Brussels
Belgium
Manufacturer
Wyeth Farma, S.A.
Autovía del Norte A-1 Km 23
Desvío Algete Km 1
28700 San Sebastián de los Reyes
Madrid
Spain
You can request more information about this medicine by contacting the local representative of the marketing authorization holder.
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA Tel: +32 (0)2 554 62 11 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4000 |
България Пфайзер България ЕООД Тел: +359 2 970 4333 | Magyarország Pfizer Kft. Tel.: + 36 1 488 37 00 |
Česká republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Malta Vivian Corporation Ltd. Tel: +356 21344610 |
Danmark Pfizer ApS Tlf.: +45 44 20 11 00 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
Ελλάδα Pfizer Ελλάς Α.Ε Τηλ: +30 210 6785800 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
España Pfizer S.L. Tel: +34 91 490 99 00 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | România Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 00 |
Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 777 | Slovenija Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0) 1 52 11 400 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: 1800 633 363 (toll free) Tel: +44 (0)1304 616161 | Slovenská republika Pfizer Luxembourg SARL, organizacná zložka Tel: + 421 2 3355 5500 |
Ísland Icepharma hf. Sími: +354 540 8000 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Sverige Pfizer AB Tel: + 46 (0)8 550 520 00 |
Κύπρος Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ: +357 22817690 | |
Latvija Pfizer Luxembourg SARL filiale Latvija Tel: +371 670 35 775 |
Date of Last Revision of this Prospectus: 02/2025.
Detailed information about this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for REFACTO AF 2000 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION IN PRE-FILLED SYRINGE – subject to medical assessment and local rules.